tamsulosin + solifenacin

Tamsulosin + solifenacin is an investigational combination therapy being evaluated by Ain Shams University for the management of ureteral stent-related symptoms. The therapy consists of tamsulosin, an alpha-1 adrenergic receptor antagonist, and solifenacin, a muscarinic receptor antagonist. Tamsulosin works by relaxing the smooth muscle in the ureter and bladder neck to facilitate urine flow and reduce pain, while solifenacin targets muscarinic receptors in the bladder to decrease detrusor overactivity and irritative voiding symptoms. This combination is specifically studied to alleviate lower urinary tract symptoms (LUTS) such as urgency, frequency, dysuria, and flank pain in patients with indwelling ureteral stents. Clinical research conducted at Ain Shams University Hospital compared standard doses (0.4 mg tamsulosin and 5 mg solifenacin) against double doses (0.8 mg tamsulosin and 10 mg solifenacin), finding the higher dose regimen more effective in symptom reduction despite an increased incidence of side effects like dry mouth and retrograde ejaculation.

Brand names

TamsulinSofenacin

Other names

tamsulosin and solifenacin combination therapy